Mazdutide
A dual GLP-1/glucagon receptor agonist studied in the same drug class as leading metabolic-health compounds.
Overview
Mazdutide is a dual-receptor agonist peptide currently in clinical development, targeting both the GLP-1 and glucagon receptors. It belongs to the same broad class of incretin-based metabolic compounds as semaglutide and tirzepatide, but with a distinct receptor-activity profile. Clinical trials for this compound are ongoing in several countries, primarily for metabolic-health indications.
Mechanism of Action
By activating both the GLP-1 receptor (which slows gastric emptying and increases satiety) and the glucagon receptor (which increases energy expenditure), Mazdutide is studied for a combined effect on appetite regulation and metabolic rate that single-receptor GLP-1 agonists don’t provide on their own. This dual-agonist approach is an active area of pharmaceutical research across several companies.
Cited Research
Dual-receptor agonist pharmacology
Characterized Mazdutide’s combined GLP-1/glucagon receptor activity profile.
Body-weight clinical trials
Studied in Phase 2/3 clinical trials for body-weight and metabolic-marker outcomes.
Comparative incretin research
Frequently discussed alongside other GLP-1-class compounds in comparative research reviews.
This is a summary, not an exhaustive review. Search the primary literature yourself: Mazdutide on PubMed →
Safety & Handling
The research-grade Mazdutide sold by Stack Science should be handled only by qualified personnel in a laboratory setting, stored and reconstituted per its Certificate of Analysis, and kept refrigerated once reconstituted. It is still in clinical trials and is not approved for any human or veterinary use.
Frequently Asked Questions
Is Mazdutide approved by the FDA?
No. It remains in clinical trials as of this writing. The research-grade material sold here is intended strictly for laboratory research, not human use.
How is Mazdutide different from semaglutide or tirzepatide?
Semaglutide targets only the GLP-1 receptor; tirzepatide targets GLP-1 and GIP receptors; Mazdutide targets GLP-1 and glucagon receptors — a distinct dual-agonist combination.
Is research-grade Mazdutide legal to purchase?
Yes, it’s legal to sell and purchase for laboratory research purposes in the U.S.
Is this page medical advice?
No. This page summarizes published literature for research and educational context only. It does not recommend a dose, protocol, or use in humans or animals outside a laboratory setting.
Have a specific question about Mazdutide?
Ask Signal IQ Rx — our research assistant trained on the Signal Library.